SOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 4:05 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s websit ...

点击注册小程序 特别申明： 查看完整报告 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 公司发布2025年半年报，实现收入5.19亿美元（YOY+81.92%）；实现归母净利润-2546.2万美元，同比大 幅缩窄；实现经调整净利润1.78亿美元（YOY+509.6%）。公司收入及经调整净利润大幅增加，主要得益 于礼新医药带来的许可收益。 点评： 生命科学业务加速转型，自动化与全球化两翼齐飞 2025H1，生命科学服务及产品板块实现收入2.48亿美元（YOY+11.3%）；实现经调整毛利1.26亿美元 （YOY+5.3%）；实现经调整经营利润4640万美元，同比略降，系公司加大营销转型与研发投入以强化中 长期竞争力。公司积极布局全球生命科学服务产能，对蛋白质、基因编辑等平台进行创新及自动化升级， 预计到20 ...

Market Overview - The Hong Kong stock market experienced a decline of 0.24% amid complex external conditions and concerns over upcoming remarks by Federal Reserve Chairman Jerome Powell at the Jackson Hole conference [1] - The geopolitical situation remains tense, with reports of large-scale airstrikes by Russian forces on Ukraine and renewed military actions in the Middle East [1][2] Company Performance - Chinese gold stocks, such as China Gold International (02099) and Chow Sang Sang (00116), saw significant gains, with increases of nearly 5% and over 7% respectively [1] - The Hong Kong Stock Exchange (HKEX) is considering extending trading hours, with plans for a 24-hour trading mechanism by 2026, although this may not be favorable for all investors [2] Digital Currency Developments - China is reportedly considering allowing the use of RMB-backed stablecoins, which could significantly enhance the internationalization of the RMB [3] - Related stocks in the stablecoin sector, such as ZhongAn Online (06060) and Guotai Junan International (01788), experienced notable increases [3] Health Sector Insights - The Chinese government has issued guidelines to promote ear and hearing health, which has positively impacted healthcare stocks like Dingdang Health (09886) and Ping An Good Doctor (01833) [3] Transportation and Logistics - China Railway Group announced a significant tender for high-speed trains, exceeding market expectations, which is likely to benefit companies like CRRC (01766) and Times Electric (03898) [3] - The shipping sector is poised for growth, particularly with the increase in trade with ASEAN countries, benefiting companies such as China Ocean Shipping (00598) and Sea Group (01308) [6] Individual Stock Highlights - Sea Group (01308) reported a revenue of approximately $1.6645 billion, a year-on-year increase of 28%, with a profit growth of 79.5% [7] - The company is expanding its fleet with new container ships to meet growing operational demands, which is expected to enhance its market position [8] - The demand for smaller container ships remains strong due to limited supply and economic growth in Southeast Asia [8]

Core Viewpoint - Kingsoft Biotech (01548) reported significant growth in its mid-term performance, with a notable increase in revenue and a substantial reduction in losses, indicating a positive trend for the company moving forward [1] Financial Performance - The revenue from continuing operations reached $519 million, representing a year-on-year increase of 81.92% [1] - The loss attributable to the parent company narrowed to $25.46 million, a reduction of 85.46% year-on-year [1] - Adjusted net profit stood at $178 million, showing a remarkable growth of 509.6% compared to the previous year [1] CDMO Segment - The CDMO revenue for the first half of the year amounted to $250 million, reflecting a year-on-year increase of 511.1% [1] - Confirmed and received payments related to the one-time advance from the collaboration with Lixin totaled $214 million, with a double-digit growth rate when excluding this amount [1] Impact of Joint Ventures - The losses from the joint venture Legend Biotech impacted Kingsoft Biotech by $194 million, contributing to the net loss reported [1] - Legend Biotech is expected to achieve adjusted net profit in the second quarter of 2025 and aims for overall profitability by 2026 [1] - The core product CARVYKTI from Legend Biotech generated net sales of $439 million in the second quarter of 2025, marking a year-on-year growth of 136%, which is anticipated to support significant improvement in Kingsoft Biotech's net profit by 2026 [1]

Core Viewpoint - Kingsoft Biotech (01548) reported significant growth in its interim results, with a notable increase in revenue and a substantial reduction in losses, indicating a positive trajectory for the company [1] Financial Performance - The revenue from continuing operations reached $519 million, representing a year-on-year increase of 81.92% [1] - The loss attributable to the parent company narrowed to $25.46 million, a reduction of 85.46% compared to the previous year [1] - Adjusted net profit stood at $178 million, showing a remarkable year-on-year growth of 509.6% [1] CDMO Segment - The CDMO (Contract Development and Manufacturing Organization) revenue for the first half of the year was $250 million, reflecting a year-on-year increase of 511.1% [1] - A one-time prepayment related to the partnership with Lixin has been confirmed and received, amounting to $214 million, with a double-digit growth rate when excluding this amount [1] Impact of Joint Ventures - The joint venture with Legend Biotech resulted in a loss impact of $194 million for the first half of the year, affecting Kingsoft Biotech's net profit [1] - Legend Biotech is expected to achieve adjusted net profit in the second quarter of 2025 and aims for overall profitability by 2026 [1] - The core product CARVYKTI from Legend Biotech achieved net sales of $439 million in the second quarter of 2025, marking a year-on-year growth of 136%, which is anticipated to support Kingsoft Biotech's net profit improvement in 2026 [1]

Core Insights - The article highlights the significant growth and strategic advancements of the company, Kingsoft, in the context of a rapidly evolving global environment, particularly in the innovative pharmaceutical sector [1][21] - The company has achieved remarkable financial results in the first half of 2025, with a substantial increase in revenue and profit, indicating strong operational resilience and growth potential [2][16] Financial Performance - In the first half of 2025, the company reported a revenue of $518.8 million, representing a year-on-year increase of 81.9% [2] - The gross profit reached $320.6 million, up 140.1% year-on-year, while the adjusted net profit from continuing operations surged to $178 million, a staggering increase of 509.6% [2] - The company’s cash reserves stood at $967 million as of June 30, 2025, providing a solid foundation for future research and development investments [2] Business Segments - **Life Sciences Services and Products**: This segment generated $247.6 million in revenue, a growth of 11.3% year-on-year, with a notable increase in the share of custom protein services [5][6] - **Biopharmaceutical CDMO**: The CDMO business saw a remarkable revenue increase of 511.1% to $246.9 million, driven by advancements in antibody protein drugs and cell gene therapy [10][11] - **Industrial Synthetic Biology Products**: Revenue in this segment reached $28.3 million, growing by 8.4% year-on-year, with strong performance in the enzyme market [13] - **Cell Therapy**: The company’s joint venture, Legend Biotech, reported net sales of approximately $439 million for CARVYKTI, marking a 136% increase, with expectations of reaching operational breakeven by the end of 2025 [14] Strategic Initiatives - The company is focusing on global expansion and automation, with plans to achieve full automation in its four major factories by the end of 2025, enhancing production efficiency and supply chain resilience [6][17] - Kingsoft is leveraging its technological advancements and strategic partnerships to enhance its market position and drive future growth [16][19] Market Outlook - The recovery of the innovative pharmaceutical market is expected to boost demand for CXO services, providing ongoing growth momentum for the company [16] - The company’s management is optimistic about future performance, projecting a revenue growth of 13%-15% for the life sciences business and maintaining a strong outlook for its other segments [18][19]

Investment Rating - The report maintains a "Buy" rating for Galaxy Entertainment Group with a target price of HKD 49.81, representing a potential upside of 26.61% from the current stock price of HKD 39.34 [2][10]. Core Insights - Galaxy Entertainment Group reported strong Q2 2025 results with a net revenue increase of 10.3% year-on-year and 7.5% quarter-on-quarter, reaching HKD 12.04 billion, which is 91.4% of the 2019 level [5]. - The adjusted EBITDA grew by 12.4% year-on-year and 8.3% quarter-on-quarter to HKD 3.57 billion, with an EBITDA margin of 29.6% [5]. - The company announced an interim dividend of HKD 0.7 per share, raising the payout ratio to 59%, marking it as the first in the industry to increase dividends [5]. - The introduction of smart gaming tables and the launch of the Capella Hotel and Resort are expected to enhance market share and attract high-quality customers [10]. Summary by Sections Galaxy Entertainment Group Performance - Q2 2025 net revenue was HKD 12.04 billion, a 10.3% increase year-on-year and a 7.5% increase quarter-on-quarter [5]. - VIP gaming table turnover increased by 20.8% year-on-year and 20.2% quarter-on-quarter [5]. - The adjusted EBITDA reached HKD 3.57 billion, with a year-on-year growth of 12.4% [5]. Hotel and Casino Operations - "Galaxy Macau" and the StarWorld Hotel reported net revenues of HKD 10 billion and HKD 1.17 billion, respectively, with year-on-year growth of 16% and a decrease of 11.5% [6]. - The EBITDA for "Galaxy Macau" was HKD 3.33 billion, reflecting a 19.5% year-on-year increase [6]. Future Developments - The Capella Hotel and Resort is set to officially open soon, featuring high-end amenities aimed at attracting a new customer base [7]. - The ongoing construction of the fourth phase of "Galaxy Macau" is expected to be completed by 2027, adding significant capacity and facilities [7]. Financial Projections - The report forecasts total net income for 2025 at HKD 47.2 billion, with a year-on-year growth of 8.7% [12]. - The projected EBITDA for 2025 is HKD 13.86 billion, reflecting a 13.7% increase [12]. - The expected net profit for 2025 is HKD 10.13 billion, with a year-on-year growth of 15.7% [12].

Core Insights - A well-balanced retirement portfolio should include a mix of defensive and growth stocks, exemplified by investments in Johnson & Johnson (JNJ) for stability and Apple Inc. (AAPL) for growth potential [1] Johnson & Johnson (JNJ) - JNJ is a reliable investment due to its position as a leading provider of essential healthcare products, demonstrating resilience with a 4.6% increase in operational sales in Q2 2025 despite losing exclusivity for its drug STELARA [2][9] - The company's diversified business model includes important medicines and life-saving medical devices, reducing dependency on any single product and enhancing stability [3] - JNJ's strong balance sheet features $19 billion in cash and marketable securities, with a debt-to-capitalization ratio of 39.3%, allowing it to navigate unfavorable business conditions effectively [4] - The company generated substantial free cash flow of $6 billion in Q2 2025, which is strategically allocated towards mergers and acquisitions, as well as returning capital to shareholders through dividends and share repurchases [5][9] - JNJ is currently trading at a trailing 12-month P/E of 17.15x, below the industry average of 22.26x, indicating it may be undervalued and presenting an attractive entry point for investors [12] Apple Inc. (AAPL) - AAPL is not just a seller of devices but is creating a connected ecosystem that fosters customer loyalty [7] - In fiscal Q3 2025, AAPL's sales increased by 13% due to new iPhone releases, with Mac sales rising 15% and record revenue from its Services segment [8][9] - The number of Apple devices in use worldwide has reached a new record, indicating strong brand loyalty and customer retention [10] - AAPL has significant growth opportunities through innovation, including advancements in artificial intelligence, new products like the Vision Pro headset, and expansion into emerging markets such as India and the Middle East [11] - AAPL is currently trading at a trailing P/E of 30.31x, which is higher than the industry average of 28.38x, suggesting that the stock is relatively expensive at current levels [13]

Core Viewpoint - Kingsray Biotechnology's affiliate Legend Biotech reported preliminary sales of CARVYKTI at approximately $439 million for the quarter ending June 30, 2025, indicating strong market expansion outside the U.S. [2][3] Group 1: Company Performance - Kingsray Biotechnology's stock rose by 8.19%, with a market capitalization of HKD 36.29 billion following the announcement [2] - Johnson & Johnson's Q2 2025 revenue reached $23.74 billion, a 5.8% year-over-year increase, surpassing market expectations [2] - CARVYKTI's sales for Q2 2025 were $439 million, reflecting a significant growth trajectory [3] Group 2: Product Insights - CARVYKTI is the first and only CAR-T cell therapy to show superior results compared to standard care in multiple myeloma, having treated over 6,000 patients globally [3] - Legend Biotech aims to double its commercial supply of CARVYKTI by 2025, targeting an annualized dose of 10,000 by the end of this year and 20,000 by the end of 2027 [3] Group 3: Market Position - Johnson & Johnson holds a leading position in multiple myeloma treatment, with approximately 80% of patients using its drugs at some point during their treatment journey [4] - Management believes CARVYKTI has the potential to exceed $5 billion in annual sales, positioning it as a blockbuster brand [4]

Group 1: Market Overview - The Hang Seng Index rose by 0.07%, gaining 17 points to close at 24,534 points, while the Hang Seng Tech Index increased by 0.29% [1] - The early trading volume in the Hong Kong stock market reached HKD 128.7 billion [1] Group 2: Innovative Drug Sector - The innovative drug sector is experiencing a resurgence, driven by favorable policies and expectations from BD, with institutions noting that the current valuations remain attractive [1] - The Hang Seng Biotechnology Index surged by 4.41% [1] Group 3: Notable Stock Performances - Lepu Biotech-B (02157) saw a significant increase of over 13% [1] - Kangfang Biotech (09926) rose by 10.16% [1] - Kangruoya-B (02162) increased by 12.4% [1] - Sangfor Biopharma (01530) gained 8.94% [1] - Fudan Zhangjiang (01349) surged by 23.9% due to progress in ADC platform development [2] - King’s Ray Biotech (01548) increased by over 6%, with CARVYKTI sales in Q2 growing approximately 136% year-on-year [3] - Ascentage Pharma-B (06855) rose by 4.87%, with recent fundraising exceeding HKD 1.49 billion and the approval of a new drug application [4] - Terns Pharmaceuticals-B (02137) increased by over 6% after granting exclusive rights for a new drug in Greater China [5] - BeiGene (06160) rose by 8.39% after the acceptance of a listing application for a dual-specificity antibody [6] - Damai Entertainment (01060) increased by 7.27%, becoming the official channel for Scottish Super League matches [7] - Bilibili-W (09626) rose by over 4%, with growth in gaming and advertising business leading to a target price upgrade by Bank of America [8] - Fenbi (02469) surged by over 14% following the release of its AI test preparation program, with expectations of improved profit margins due to increased penetration [9] - Smoore International (06969) fell by 1%, with expected net profit decline of up to 35% in the first half of the year due to rising expenses [10]